The clinical genomics of prostate cancer

Michael Fraser; Theo van der Kwast; Paul C. Boutros; Robert G. Bristow

doi:10.1007/978-3-319-42769-0_6

The clinical genomics of prostate cancer

Michael Fraser, Theo van der Kwast, Paul C. Boutros, Robert G. Bristow

Division of Cancer Sciences (L5)

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Herein we summarize clinically applicable aspects of the molecular landscape of prostate cancer (PCa), including molecular heterogeneity and subclonality during prostate tumorigenesis and progression. We discuss the major molecular aberrations that define both localized and metastatic prostate cancer and contrast these unique disease states. Finally, we describe the potential utility of using molecular aberrations as prognostic and predictive biomarkers for biochemical and metastatic recurrence, as well as for targeted therapeutics for metastatic castration-resistant prostate cancer.

Original language	English
Title of host publication	Management of Prostate Cancer
Subtitle of host publication	A Multidisciplinary Approach
Editors	Michel Bolla, Hendrik van Poppel
Place of Publication	Cham
Publisher	Springer Nature
Pages	97-110
Number of pages	14
Edition	Second
ISBN (Electronic)	9783319427690
ISBN (Print)	9783319427683
DOIs	https://doi.org/10.1007/978-3-319-42769-0_6
Publication status	Published - 1 Jan 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-42769-0_6

Cite this

@inbook{ce82353863904960a96979c37a3cba17,

title = "The clinical genomics of prostate cancer",

abstract = "Herein we summarize clinically applicable aspects of the molecular landscape of prostate cancer (PCa), including molecular heterogeneity and subclonality during prostate tumorigenesis and progression. We discuss the major molecular aberrations that define both localized and metastatic prostate cancer and contrast these unique disease states. Finally, we describe the potential utility of using molecular aberrations as prognostic and predictive biomarkers for biochemical and metastatic recurrence, as well as for targeted therapeutics for metastatic castration-resistant prostate cancer.",

author = "Michael Fraser and {van der Kwast}, Theo and Boutros, {Paul C.} and Bristow, {Robert G.}",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/978-3-319-42769-0_6",

language = "English",

isbn = "9783319427683",

pages = "97--110",

editor = "Bolla, {Michel } and {van Poppel}, Hendrik",

booktitle = "Management of Prostate Cancer",

publisher = "Springer Nature",

address = "United States",

edition = "Second",

}

TY - CHAP

T1 - The clinical genomics of prostate cancer

AU - Fraser, Michael

AU - van der Kwast, Theo

AU - Boutros, Paul C.

AU - Bristow, Robert G.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Herein we summarize clinically applicable aspects of the molecular landscape of prostate cancer (PCa), including molecular heterogeneity and subclonality during prostate tumorigenesis and progression. We discuss the major molecular aberrations that define both localized and metastatic prostate cancer and contrast these unique disease states. Finally, we describe the potential utility of using molecular aberrations as prognostic and predictive biomarkers for biochemical and metastatic recurrence, as well as for targeted therapeutics for metastatic castration-resistant prostate cancer.

AB - Herein we summarize clinically applicable aspects of the molecular landscape of prostate cancer (PCa), including molecular heterogeneity and subclonality during prostate tumorigenesis and progression. We discuss the major molecular aberrations that define both localized and metastatic prostate cancer and contrast these unique disease states. Finally, we describe the potential utility of using molecular aberrations as prognostic and predictive biomarkers for biochemical and metastatic recurrence, as well as for targeted therapeutics for metastatic castration-resistant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85028815772&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-42769-0_6

DO - 10.1007/978-3-319-42769-0_6

M3 - Chapter

AN - SCOPUS:85028815772

SN - 9783319427683

SP - 97

EP - 110

BT - Management of Prostate Cancer

A2 - Bolla, Michel

A2 - van Poppel, Hendrik

PB - Springer Nature

CY - Cham

ER -

The clinical genomics of prostate cancer

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this